Market Research Report
Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023
|Published by||BCC Research||Product code||860081|
|Published||Content info||277 Pages
Delivery time: 1-2 business days
|Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023|
|Published: May 31, 2019||Content info: 277 Pages||
The global market for liquid biopsy should grow from $2.3 billion in 2018 to reach $6.1 billion by 2023 at a compound annual growth rate (CAGR) of 21.1% for the period of 2018-2023.
Noncancer as a segment of liquid biopsy market should grow from $1.9 billion in 2018 to reach $3.7 billion by 2023 at a CAGR of 14.1% for the period of 2018-2023.
Cancer as a segment of liquid biopsy market should grow from $411.7 million in 2018 to reach $2.4 billion by 2023 at a CAGR of 41.7% for the period of 2018-2023.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).
This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report discusses several significant, large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments, droplet digital PCR (polymerase chain reaction), target enrichment, single-cell DNA polymerase, non-invasive prenatal testing (NIPT), fetal-cell NIPT, CTC (circulating tumor cell) capture and detection and liquid biopsy.
The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/ early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia Pacific, Rest of the World).
Market data covers 2017, 2018 and 2023 (forecasted).
More than 175 companies in the liquid biopsy industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.